Plk1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer.

@article{Zhang2014Plk1IE,
  title={Plk1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer.},
  author={Zhe Zhang and Xianzeng Hou and Chen Shao and Junjie Li and Ji Xin Cheng and Shihuan Kuang and Nihal Ahmad and Timothy L Ratliff and X John{\'e} Liu},
  journal={Cancer research},
  year={2014},
  volume={74 22},
  pages={6635-47}
}
Prostate cancer is thought to be driven by oxidative stress, lipid metabolism, androgen receptor (AR) signaling, and activation of the PI3K-AKT-mTOR pathway, but it is uncertain how they may become coordinated during progression to castration-resistant disease that remains incurable. The mitotic kinase polo-like kinase 1 (Plk1) is elevated in prostate cancer, where its expression is linked to tumor grade. Notably, Plk1 signaling and lipid metabolism were identified recently as two of the top… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 2 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 41 references

Enzalutamide in metastatic prostate cancer before chemotherapy.

The New England journal of medicine • 2014
View 7 Excerpts
Highly Influenced

Plk1 phosphorylation of PTEN causes a tumor-promoting metabolic state.

Molecular and cellular biology • 2014
View 1 Excerpt

Abiraterone in metastatic prostate cancer.

The New England journal of medicine • 2013
View 1 Excerpt

Similar Papers

Loading similar papers…